About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/10/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/10/2020.

Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea

Clinicaltrials.gov identifier NCT03288974

Recruitment Status Recruiting

First Posted September 20, 2017

Last update posted May 11, 2020

Study Description

Brief summary:

PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib The primary objective of this Drug Use Examination (DUE) is to evaluate safety of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea. The secondary objective of this DUE is to evaluate effectiveness of POMALYST® (Pomalidomide) treatment of multiple myeloma in the clinical routine practice in Korea.

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Drug: POMALYST® (Pomalidomide)
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 600 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
  • Actual Study Start Date: December 2017
  • Estimated Primary Completion Date: June 2023
  • Estimated Study Completion Date: June 2023
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Post Marketing Survey of MM patients treated with POMALYST®
As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
Drug: POMALYST® (Pomalidomide)
The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
Outcome Measures
  • Primary Outcome Measures: 1. Adverse events [ Time Frame: From enrollment until at least 28 days after completion of study treatment ]
    Any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment, i.e., any unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.se temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.
  • Secondary Outcome Measures: 1. Overall response rate [ Time Frame: Up to approximately 5.6 months ]
    The percentage of patients who achieve CR (complete response), sCR (stringent complete response), Immunophenotypic CR, Molecular CR, VGPR (very good partial response) and PR (partial response) will be evaluated as overall response rate during POMALYST® treatment period based on International Myeloma Working Group Criteria for Multiple Myeloma. Analysis and reporting for efficacy will be done at every 6months for the first 2years and after then, annual report(3,4,5th yearly report) and CSR for all data of 6years will be submitted to MFDS in accordance with MFDS guideline.
Eligibility Criteria
  • Ages Eligible for Study: 19 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients who are treated with POMALYST® based on the following criteria, can be registered into this DUE. •POMALYST® in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib.
Criteria

Inclusion Criteria:

The main criteria for inclusion of this DUE is the same as the approved package insert of
POMALYST® in Korea. Based on the current PI, patients who are treated with POMALYST® based
on the following criteria, can be registered into this DUE.

- POMALYST® in combination with dexamethasone is indicated in the treatment of patients
with relapsed and refractory multiple myeloma who have received at least two prior
treatment regimens, including both lenalidomide and bortezomib.

The actual inclusion criteria and patient population who can start with POMALYST® treatment
will be narrowed down according to the local health insurance reimbursement condition.

Exclusion Criteria:

- There's no exclusion criteria

Contacts and Locations
Contacts

Contact: Karen Kim, Assoc. Mgr, Medical Affairs +82 2 3469 7962 kakim@celgene.com

Contact: Ji-Hyun Park, Specialist, Medical Affairs +82 2 3469 7837 jhpark@celgene.com

Locations
Show 29 Study Locations
Sponsors and Collaborators

Celgene

Investigators

Study Director: Claire Lee, Senior Medical Advisor Celgene Korea

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT03288974 History of Changes
  • Other Study ID Numbers: NIPMS-POM-KR-001, U1111-1201-1712
  • First Posted: September 20, 2017 Key Record Dates
  • Last Update Posted: May 11, 2020
  • Last Verified: May 2020
  • Keywords provided by Celgene: Multiple Myeloma
    POMALYST®
    Pomalidomide
    Observational
    Korea
    Post Marketing Surveillance[PMS]
    Relapsed and Refractory Multiple Myeloma
  • Additional relevant MeSH terms: Multiple Myeloma Neoplasms, Plasma Cell